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A B S T R A C T
Purpose: Epilepsy patients have a signiﬁcantly higher rate of anxiety and depression than the general
population, and psychiatric disease is particularly prevalent among drug resistant epilepsy patients.
Symptoms of anxiety and depression might serve as a barrier to appropriate epilepsy care.
The aim of this study was to determine if drug resistant epilepsy patients with symptoms of anxiety
and/or depression receive different epilepsy management than controls.
Method: We identiﬁed 83 patients with drug resistant focal epilepsy seen at the Penn Epilepsy Center.
Upon enrollment, all patients completed 3 self-report scales and a neuropsychiatric inventory and were
grouped into those with symptoms of anxiety and/or depression and controls. Each patient’s medical
records were retrospectively reviewed for 1–2 years, and objective measures of outpatient and inpatient
epilepsy management were assessed.
Results: At baseline, 53% (n = 43) of patients screened positive for symptoms of anxiety and/or
depression. The remaining 47% (n = 38) served as controls. Patients with anxiety and/or depression
symptoms had more missed outpatient visits per year compared to controls (median 0.84 vs. 0.48,
p = 0.02). Patients with symptoms of both anxiety and depression were more likely to undergo an
inpatient admission or procedure (56% vs. 24%, p = 0.02).
Conclusion: For most measures of epilepsy management, symptoms of anxiety and/or depression do not
alter epilepsy care; however, drug resistant epilepsy patients with anxiety and/or depression symptoms
may be more likely to miss outpatient appointments, and those with the highest burden of psychiatric
symptoms may be admitted more frequently for inpatient services compared to controls.
 2013 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Patients with epilepsy (PWE) suffer from depression and
anxiety more than the general population.1 Psychiatric disease
is particularly prevalent among patients with localization-related
epilepsy (LRE) of temporal or frontal lobe origin,2,3 and depressionAbbreviations: PWE, patients with epilepsy; LRE, localization-related epilepsy; AED,
anti-epileptic drug; ASERT, Assessment of Suicidality in Epilepsy: Rating Tools; BDI-
II, Beck Depression Inventory-II; NDDI-E, Neurologic Disorders Depression
Inventory-Epilepsy; PHQ-GAD 7, Patient Health Questionnaire-Generalized Anxiety
Disorder 7; MINI, Mini International Neuropsychiatric Interview; MDD, major
depressive disorder; EMU, epilepsy monitoring unit; VNS, vagus nerve stimulator;
IQR, interquartile range.
* Corresponding author at: Penn Epilepsy Center, Department of Neurology,
University of Pennsylvania, 3 West Gates, 3400 Spruce Street, Philadelphia, PA
19104, USA. Tel.: +1 215 349 5166.
E-mail address: john.pollard@uphs.upenn.edu (J.R. Pollard).
1059-1311/$ – see front matter  2013 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2013.11.012and anxiety are more common in patients whose epilepsy is poorly
controlled and experience at least one seizure per month.4,5 The
relationship between psychiatric illness and epilepsy is complex
and bidirectional.6–11 Stress, anxiety and depression are closely
linked in the general population,12 and these psychiatric symp-
toms frequently coexist in PWE as well.13
Identifying barriers to epilepsy care is an active area of research
in light of recent attempts to establish standards of epilepsy
management.14,15 Racial minorities and the uninsured have worse
access to epilepsy care, as assessed by measures such as
compliance and prescriptions ﬁlled for new anti-epileptic drugs
(AEDs).16,17 These populations are also less likely to undergo
resective surgery for drug resistant epilepsy18 despite recommen-
dations to consider surgery in all patients who have failed 2
AEDs.19
Although psychiatric disorders are common among drug
resistant LRE patients, no study to date has examined how
comorbid anxiety and depression affect these patients’ epilepsyvier Ltd. All rights reserved.
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and/or depression receive substandard epilepsy care, since these
patients may be more likely to avoid new therapies and invasive
testing. We tested this hypothesis using a cohort of patients with
active symptoms of anxiety and/or depression to determine if their
outpatient and inpatient management differed from epilepsy
controls without anxiety and/or depression.
2. Methods
2.1. Subjects
Subjects were recruited from the Epilepsy Center at the
University of Pennsylvania. Patients had been previously enrolled
in the ASERT trial, ‘‘Assessment of Suicidality in Epilepsy: Rating
Tools (ASERT)’’.20 Inclusion criteria for enrollment were (1)
diagnosis of partial epilepsy for at least 2 years; (2) experiencing
at least 1 seizure per month; and (3) receiving 1–3 AEDs. Patients
with psychogenic non-epileptic seizures and those carrying a
diagnosis of a major psychotic disorder were excluded. Partici-
pants signed an informed consent form approved by the
Institutional Review Board. For each subject, we assessed age,
gender, ethnicity, employment, education, and whether they were
followed by an attending neurologist vs. a resident or nurse
practitioner. We also recorded seizure characteristics, including
duration of epilepsy, number of seizures per month, and presence
of convulsions.
2.2. Assessment of anxiety and depression symptoms
At ASERT enrollment (baseline), participants completed a set of
psychiatric questionnaires, including the Beck Depression Inven-
tory-II (BDI-II), the Neurologic Disorders Depression Inventory-
Epilepsy (NDDI-E), and the Patient Health Questionnaire-General-
ized Anxiety Disorder 7 (PHQ-GAD 7). The BDI-II is a widely used
self-report depression screen21 that has been validated to screen
for major depressive disorder (MDD) in PWE who score above 15.22
The NDDI-E was developed to screen for depression among PWE
and predicts MDD at a score >15.23 Although to date, no anxiety
questionnaires have been developed speciﬁcally for PWE,24 the
PHQ-GAD 7 has been used to screen for GAD and other anxiety
disorders in primary care settings in patients scoring a 10 or
above.25 In addition to self-report measures, patients were also
evaluated for active psychiatric disorders using the Mini Interna-
tional Neuropsychiatric Interview (MINI) 5.5.0 (Version 2), which
has good correlation to the Structured Clinical Interview for DSM-
IV Axis I Disorders, the gold standard for identifying a comorbid
mood disorder in PWE.26
Patients were categorized as having symptoms of depression if
they had a DSM-IV diagnosis on the MINI or scored above a 15 on
the BDI-II or NDDI-E. Patients were considered to have symptoms
of anxiety if they had a DSM-IV diagnosis on the MINI or scored a 10
or greater on the PHQ-GAD 7.
None of the subjects had psychiatric illnesses severe enough to
require admissions for their psychiatric diagnoses or housing in a
psychiatric facility. Patients’ anxiety and depression were man-
aged primarily by their neurologist at the Epilepsy Center at the
University of Pennsylvania. A minority of patients were referred to
or seen by outpatient psychiatrists or psychologists.
2.3. Assessment of epilepsy management
Patients’ medical records were retrospectively reviewed start-
ing from the time of their enrollment in the ASERT study until
August 2012. Records were no longer reviewed after a patient
stopped receiving care at the Penn Epilepsy Center. Informationabout patients’ epilepsy management was obtained mostly from
their outpatient neurology notes.
Epilepsy management was divided into three categories:
outpatient medical management, inpatient management, and
patient adherence. Measures of outpatient medical management
included number of adjustments to AED doses, starting or stopping
an AED, and changes in dose or type of rescue medications or
benzodiazepines. Measures of inpatient management were admis-
sions to the epilepsy monitoring unit (EMU) for purposes of
epilepsy diagnosis or surgical work-up, placement of a vagus nerve
stimulator (VNS), and resective surgery. Measures of poor patient
adherence included number of missed outpatient appointments
and missed labs or imaging (i.e. labs or imaging were ordered for
the patient but never completed). Whether or not patients
achieved seizure freedom, as deﬁned as the absence of seizures
for >6 months, was also noted as a clinical outcome.
2.4. Group comparisons and statistical analysis
Since records were retrospectively reviewed for different
lengths of time depending on their ASERT enrollment date,
management events for a particular patient were divided by the
total number of years that patient had been followed, in order to
standardize outcome measures across patients. Outcome mea-
sures of epilepsy management were assessed in controls compared
to patients with reported symptoms of anxiety and/or depression
at enrollment. The main comparison was between controls and
patients with symptoms of depression and/or anxiety, but in a
secondary analysis, comparisons were conducted between con-
trols, patients with only symptoms of depression or anxiety, and
patients with symptoms of both depression and anxiety.
Group comparisons were calculated using parametric and non-
parametric tests, and linear regression models were constructed to
determine independent associations with each outcome measure.
3. Results
3.1. Baseline subject characteristics
Eighty-three participants were initially consented to partici-
pate, and 81 responded to all psychiatric questionnaires. At
baseline, 53% (n = 43) of patients had either a diagnosis of anxiety
or depression on the MINI (n = 23) and/or screened positive on any
of the three screens (n = 20), and 47% (n = 38) of patients did not
screen positive on any psychiatric screen or the MINI and served as
controls.
Table 1 shows that patients with anxiety and/or depression
symptoms were comparable with controls for all demographic
variables and epilepsy history. Table 1 also outlines patients’ mean
scores on the three anxiety and depression screens and the
percentage of patients diagnosed with depression or anxiety on the
MINI.
3.2. Epilepsy management
The median length of time a patient’s chart was reviewed was
19 months, with an interquartile range of 17–22 months. Table 1
compares epilepsy management and clinical outcomes in patients
with symptoms of anxiety and/or depression vs. controls. For
outpatient epilepsy management, patients with symptoms of
anxiety and/or depression had similar numbers of AED changes per
year as controls. The percentage achieving seizure freedom was
similar in anxious and/or depressed patients and controls. In
comparing measures of adherence, patients with depression and/
or anxiety had a greater median number of missed outpatient visits
per year than controls (0.84 vs. 0.48, p = 0.02). This effect remained
Table 1
Demographic characteristics and clinical management of patients with depressed and/or anxious symptoms compared to controls.
Depressed and/or anxious symptoms Controls p value
n = 43 n = 38
Mean age 41 45 0.18
Minority (%) 28 26 0.87
Male (%) 42 39 0.83
Some college education (%) 60 66 0.62
Employed (%) 37 58 0.06
Receiving disability beneﬁts (%) 28 21 0.61
Followed by attending neurologist (%) 91 90 1.00
Epilepsy history and severity
Duration of epilepsy, median years 10 15.5 0.06
Convulsions present (%) 47 32 0.25
Seizures per month, median 6 5.5 0.44
>2 current AEDs (%) 40 37 0.81
Past epilepsy treatments
Surgery (%) 14 18 0.59
VNS (%) 12 18 0.39
Number of AED trials, median 4 3 0.53
Comorbid medical disease
Number of other medical conditions, median 1 2 0.91
Number of non-AED prescriptions, median 1 1 0.79
Depression and anxiety screening
NDDI-E score 15
(IQR 12–17)
11
(IQR 9–13)
N/A
BDI-II score 17
(IQR 10–23)
5
(IQR 1–7)
N/A
PHQ-GAD-7 score 11
(IQR 8–13)
4
(IQR 2–6)
N/A
Diagnosis of depression on MINI (%) 16 0 N/A
Diagnosis of anxiety on MINI (%) 33 0 N/A
Outpatient epilepsy management
AED changes per year, median 1.56 1.68 0.99
Inpatient epilepsy management
Underwent surgery or VNS placement (%) 14 5 0.27
Underwent any procedure or admission (%) 37 24 0.23
Measures of patient adherence
Number of missed outpatient visits per year, median 0.84 0.48 0.02
Missed labs, imaging, or EEG per year, median 0
(IQR 0–0.71)
0
(IQR 0–0.4)
0.91
Epilepsy control
Achieved > 6 months of seizure freedom (%) 5 8 0.66
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ment status, duration of epilepsy, and current convulsions.
3.3. Subgroup differences in inpatient management
Although none of the differences in inpatient management
reached signiﬁcance when comparing the two groups, patients
with symptoms of both anxiety and depression were signiﬁcantly
more likely to undergo inpatient admissions and procedures than
controls. Fig. 1 compares the epilepsy management of controls,
patients with symptoms of only anxiety or depression, and those
with symptoms of both anxiety and depression. A signiﬁcantly
higher proportion of anxious and depressed patients underwent
any inpatient admission or procedure over the 1–2 years compared
to controls (56% vs. 24%, p = 0.02), although the proportion with
surgeries or VNS placement did not differ. In examining reasons for
admissions, there were a signiﬁcantly higher number of EMU
admissions for diagnostic purposes per year among patients with
depressed and anxious symptoms compared to controls (median 0,
interquartile range 0–0.14 vs. median 0, interquartile range 0–0,
p = 0.03), while EMU admissions for pre-surgical work-up were not
signiﬁcantly different between groups.
4. Discussion
Patients with active psychiatric symptoms of anxiety and/or
depression did not receive a different level of epilepsy carecompared to controls in most domains of epilepsy management.
However, patients with symptoms of anxiety and/or depression
did have more missed outpatient visits, and the more severely
affected patients with symptoms of both anxiety and depression
were signiﬁcantly more likely to have an inpatient admission or a
procedure compared to controls.
Among patients with other neurologic diseases, such as stroke,
depression and anxiety are associated with increased mortality,
which is thought to result in part from the psychiatric disorders
disrupting the management and recovery of these patients.27–29
Comorbid depression has been associated with worse compliance
and follow-up among patients with medical disease, due to factors
such as poor social support and self-motivation.30 This is
consistent with our ﬁnding that anxious and/or depressed epilepsy
were more likely to miss outpatient appointments than controls.
And if patients with comorbid psychiatric disease tend to have
worse compliance, then it may be unsurprising that patients with
symptoms of both anxiety and depression had more admissions for
pre-scheduled EMU evaluations or surgical procedures. Epileptol-
ogists may be particularly likely to refer their anxious and
depressed patients for inpatient evaluation, because they mistake
psychiatric symptoms for peri-ictal phenomena31 or think that
these symptoms are associated with psychogenic non-epileptic
events.32 This theory is supported by our ﬁnding that anxious and
depressed patients were signiﬁcantly more likely than controls to
be admitted to the EMU for diagnostic purposes but not for pre-
surgical work-up.
Fig. 1. Secondary analysis – subgroup comparisons. Epilepsy management in controls compared to patients with symptoms of depression OR anxiety and patients with
symptoms of depression AND anxiety. *p < 0.05 for comparison between controls and patients with depressed AND anxious symptoms.
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inpatient admissions, it is difﬁcult to conclude that patients with
anxiety and/or depression symptoms received substandard care
compared to controls. Published guidelines for epilepsy care focus
on the management of epilepsy patients in a general neurology or
primary care setting,33–35 and standards of care for drug resistant
LRE patients only dictate that patients who have failed 2 AEDs
should be referred to specialized epilepsy centers14–16 and
considered for surgery.19 Since our population was from a
specialized center offering epilepsy surgery, the care delivered
to all patients appeared to meet the minimum criteria based on
these guidelines. Also, we could not ascertain whether the more
frequent missed outpatient appointments and inpatient admis-
sions made a difference in seizure frequency based on the
imprecision of the data from outpatient notes, but these
differences in management did not affect rates of seizure freedom.
However, we wish to highlight the ﬁnding that patients with
both anxiety and depression symptoms were admitted more
frequently for inpatient services than controls, since EMU
admissions and carry signiﬁcant iatrogenic risks. We do not
believe that patients with symptoms of anxiety and depression
were admitted more frequently because they had more severe
epilepsy. Contrary to prior studies showing an association between
a greater burden of epilepsy and psychiatric disorders,4,5 we did
not ﬁnd any differences in epilepsy severity as assessed by
duration of epilepsy, number of seizures per month, number of
current AEDs, and presence of convulsions. One could also argue
that patients with psychiatric disease may be more likely to be
unemployed and therefore more available to be admitted to an
inpatient unit; however, we did not ﬁnd a signiﬁcant difference in
rates of unemployment or disability beneﬁts among patients with
anxiety and/or depression compared to controls.
There were some potential limitations of this study, which may
have affected the outcome and generalizability. Instead of
reassessing patients’ symptoms of anxiety and depression over
time, our assessment was limited to a single assessment at the time
of enrollment. Also, the anxious and/or depressed patients
included those who only scored positive on psychiatric screens,
which is not the same as the actual DSM-IV diagnoses. To account
for this, we separately examined the association between
depression and/or anxiety and missed outpatient appointments
among controls vs. anxious and/or depressed patients who scored
positive on the MINI and vs. those who only screened positive on
the psychiatric screens and found that this association was still
present.
Another limitation of this study is the small sample size, which
may not have allowed for enough power to detect some smallerdifferences in management outcomes. We only followed epilepsy
patients with drug-resistant LRE treated at a tertiary care center,
who were capable of answering surveys. Patients who seek
treatment at a specialized epilepsy center may be more likely to
take an active part in their care and comply with management
decisions, and our conclusions may not generalize to epilepsy
patients in the community. Also of note, we did not adjust the p
value to correct for multiple comparisons in this small sample size.
However, our approach was reasonable given that the study was
exploratory with the purpose of generating hypotheses.36 Future
studies can be more directed with fewer comparisons.
This study illustrates that co-morbid anxiety and depression
may lead to differences in epilepsy management. Our ﬁndings
highlight the importance of identifying and adequately treating
psychiatric disease to prevent inequalities in epilepsy care,
especially given the prevalence of anxious and depressed
symptoms among epilepsy patients.
5. Conclusions
This is the ﬁrst study to explore how comorbid psychiatric
disease affects epilepsy care. Although we had hypothesized that
symptoms of anxiety and depression would serve as a barrier to
appropriate epilepsy care, our ﬁndings suggest that patients with
symptoms of anxiety and/or depression are not receiving
substandard care in most domains of epilepsy management.
However, based on our results, epileptologists should be aware
that they may be admitting patients with symptoms of anxiety and
depression symptoms more frequently than their other patients.
Our results are limited by a small sample size and short follow-
up period. In addition, it is difﬁcult to conclude how a higher rate of
inpatient admissions may ultimately affect epilepsy outcomes. A
prospective study that includes assessments for seizure frequency
and increases the frequency of screens for anxiety and depression
should be conducted to conﬁrm our conclusions.
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